Shares of this Zacks Rank #2 (Buy) company have risen 21.9% so far this year against the industry’s 5.5% decline. The S&P 500 Index has decreased 15.6% in the same time frame. Cencora is one of ...

Has Cencora (COR) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Cencora (NYSE:COR) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

Have you been paying attention to shares of Cencora (COR)? Shares have been on the move with the stock up 8.3% over the past month. The stock hit a new 52-week high of $271.86 in the previous session.

Walgreens said after markets closed Thursday that it will use the proceeds mostly to pay down debt and for general corporate purposes. The deal reduces Walgreens’ stake in Cencora to about 10% ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cencora (COR – Research Report) and Johnson & Johnson (JNJ – Research Report). Discover ...

Shares of this Zacks Rank #3 (Hold) company have risen 13% year to date compared with the industry’s 6.6% growth. The S&P 500 Index has soared 28.6% in the same time frame. Cencora is one of the ...